Part I of this series explained China’s general rules on foreign-related jurisdiction. In Part II, Jianwei(Jerry) Fang, Ke Dong and Haoyi Sun of Zhong LunLaw Firm show how Chinese courts will, in practice, assert jurisdiction in civil, administrative or criminal contexts involving foreign elements, and describe a new “blocking statute” that reflects China’s response to foreign long-arm claims.
Qiong Wu, Yuxiang Liu, Qingqing Chen and Xiaoyi Zhuang of Haiwen & Partners provide essential insights into an essential new judicial interpretation concerning labor dispute cases, including a comparison with the current rules and judicial practice and implications for compliance and risk management practices
Eric (Ye) Zou of Merits & Tree Law Offices gives an overview of the core elements and key significance of a new pilot scheme which maps out a new way for foreign investors to access China’s flourishing financial markets
In the first part of a series of articles, Jianwei (Jerry) Fang, Ke Dong, and Haoyi Sun of Zhong Lun Law Firm outline the general jurisdiction rules governing foreign-related civil litigation in China under the 2024 Civil Procedure Law, and explain the statutory framework, key jurisdictional bases, and procedural considerations that foreign companies and in-house counsel need to understand when facing potential lawsuits in Chinese courts
Wei Huang, managing partner, and Kexin Chen, associate, at Beijing Tian Yuan Law Firm provide a comprehensive interpretation of a core provision of China’s revised Anti-Unfair Competition Law and its impact on enterprises of all sizes
A leading international healthcare General Counsel in the region provides an exclusive in-house perspective on the current law and practice of cross-border data transfer in China
Casper Sek of Jingtian & Gongcheng examines new guidance from TC260 which looks likely to become an essential component in companies’ personal information protection toolkits
The intersection between intellectual property and artificial intelligence raises challenging and significant legal issues. Danlei Wu of Fangda Partners examines China’s first case relating to the structure and parameters of an AI model
CEO and General Counsel of MyoMed Bio, explains how legal strategy—spanning IP, regulatory compliance, and cross-border structuring—is essential for enabling clinical development, managing geopolitical and data protection risks, and aligning biotech operations across China, the U.S., and Australia.
